$UPXI
UPEXI, INC. Stock $upxi

$upxi Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-K Financial Statement

#000147793224008123 Filed on December 16, 2024

Income Statement

Concept	2024 Q4	2024
Revenue	$4.005M	$26.00M
YoY Change	-81.65%	-67.77%
Cost Of Revenue	$1.031M	$13.18M
YoY Change	-92.39%	-72.04%
Gross Profit	$2.974M	$12.82M
YoY Change	-64.04%	-61.78%
Gross Profit Margin	74.25%	49.32%
Selling, General & Admin	$2.499M	$12.76M
YoY Change	-49.97%	-35.94%
% of Gross Profit	84.01%	99.51%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$220.6K	$1.268M
YoY Change	-32.88%	34.26%
% of Gross Profit	7.42%	9.89%
Operating Expenses	$4.047M	$35.29M
YoY Change	-59.76%	-14.17%
Operating Profit	-$1.073M	-$22.46M
YoY Change	-39.95%	197.44%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net	-$228.1K	-$3.141M
YoY Change	-78.82%	-71.23%
Pretax Income	-$1.301M	-$25.60M
YoY Change	-54.57%	38.61%
Income Tax	$0.00	$332.1K
% Of Pretax Income
Net Earnings	-$1.301M	-$23.66M
YoY Change	-46.62%	35.27%
Net Earnings / Revenue	-32.49%	-90.99%
Basic Earnings Per Share	-$1.24	-$23.03
Diluted Earnings Per Share	-$1.24	-$23.03
COMMON SHARES
Basic Shares Outstanding	1.041M shares	1.027M shares
Diluted Shares Outstanding	1.045M shares	1.027M shares

Balance Sheet

Concept	2024 Q4	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments		$661.4K
YoY Change		-85.27%
Cash & Equivalents	$406.3K	$661.4K
Short-Term Investments		$0.00
Other Short-Term Assets
YoY Change
Inventory	$2.236M	$1.432M
Prepaid Expenses
Receivables	$1.162M	$606.9K
Other Receivables
Total Short-Term Assets	$6.110M	$11.42M
YoY Change	-72.94%	-55.14%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.140M	$2.357M
YoY Change	-71.84%	-68.69%
Goodwill	$848.9K	$848.9K
YoY Change	-92.81%	-91.72%
Intangibles	$201.5K	$239.9K
YoY Change	-98.22%	-98.23%
Long-Term Investments
YoY Change
Other Assets	$199.9K	$278.4K
YoY Change	-54.76%	187.85%
Total Long-Term Assets	$11.42M	$12.09M
YoY Change	-71.15%	-68.51%
TOTAL ASSETS
Total Short-Term Assets	$6.110M	$11.42M
Total Long-Term Assets	$11.42M	$12.09M
Total Assets	$17.53M	$23.51M
YoY Change	-71.8%	-63.18%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.005M	$481.6K
YoY Change	-66.7%	-87.87%
Accrued Expenses	$222.1K	$736.4K
YoY Change	-91.64%	-78.12%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$10.62M	$12.66M
YoY Change	-56.23%	-35.45%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$3.149M	$4.340M
YoY Change	-74.69%	-73.55%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.62M	$12.66M
Total Long-Term Liabilities	$3.149M	$4.340M
Total Liabilities	$13.77M	$17.00M
YoY Change	-62.49%	-52.81%
SHAREHOLDERS EQUITY
Retained Earnings	-$49.79M	-$46.86M
YoY Change	84.43%	101.97%
Common Stock	$20.91K	$19.86K
YoY Change	2.94%	-1.76%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.763M	$6.516M
YoY Change
Total Liabilities & Shareholders Equity	$17.53M	$23.51M
YoY Change	-71.8%	-63.18%

Cashflow Statement

Concept	2024 Q4	2024
OPERATING ACTIVITIES
Net Income	-$1.301M	-$23.66M
YoY Change	-46.62%	35.27%
Depreciation, Depletion And Amortization	$220.6K	$1.268M
YoY Change	-32.88%	34.26%
Cash From Operating Activities		-$101.4K
YoY Change		-150.02%
INVESTING ACTIVITIES
Capital Expenditures		$932.6K
YoY Change		-0.53%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities		-$3.376M
YoY Change		31.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		-$353.8K
YoY Change		23.99%
NET CHANGE
Cash From Operating Activities		-$101.4K
Cash From Investing Activities		-$3.376M
Cash From Financing Activities		-$353.8K
Net Change In Cash		-$4.417M
YoY Change		88.58%
FREE CASH FLOW
Cash From Operating Activities		-$101.4K
Capital Expenditures		$932.6K
Free Cash Flow		-$1.034M
YoY Change		40.69%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024	dei	Entity Central Index Key EntityCentralIndexKey	0001775194
CY2024	dei	Amendment Flag AmendmentFlag	false
CY2024	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
CY2024	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2024	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2024	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 420
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	500000	shares
CY2023Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	25000	shares
CY2023Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	25000	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5000000	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1010843	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1045429	shares
CY2024	upxi	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDividendRate	0	pure
CY2023	upxi	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsDividendRate	0	pure
CY2024	srt	Mortgage Loans On Real Estate Interest Rate MortgageLoansOnRealEstateInterestRate	0.0007	pure
CY2023Q2	upxi	Valuation Reserves For Inventory ValuationReservesForInventory	6100000	usd
CY2024	dei	Document Type DocumentType	10-K
CY2024	dei	Document Annual Report DocumentAnnualReport	true
CY2024	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
CY2024	dei	Document Transition Report DocumentTransitionReport	false
CY2024	dei	Entity File Number EntityFileNumber	001-40535
CY2024	dei	Entity Registrant Name EntityRegistrantName	UPEXI, INC.
CY2024	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2024	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	83-3378978
CY2024	dei	Entity Address Address Line1 EntityAddressAddressLine1	3030 North Rocky Point Drive
CY2024	dei	Entity Address City Or Town EntityAddressCityOrTown	Tampa
CY2024	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2024	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33607
CY2024	dei	City Area Code CityAreaCode	701
CY2024	dei	Local Phone Number LocalPhoneNumber	353-5425
CY2024	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001
CY2024	dei	Trading Symbol TradingSymbol	UPXI
CY2024	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2024	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2024	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2024	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	No
CY2024	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024	dei	Entity Small Business EntitySmallBusiness	true
CY2024	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2024	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
CY2024	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Public Float EntityPublicFloat	17409735	usd
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1040924	shares
CY2024	dei	Auditor Firm AuditorFirmId	1808
CY2024	dei	Auditor Name AuditorName	GBQ Partners LLC
CY2024	dei	Auditor Location AuditorLocation	Columbus, Ohio
CY2024Q2	upxi	Due From Bloomios Current DueFromBloomiosCurrent	0	usd
CY2023Q2	upxi	Due From Bloomios Current DueFromBloomiosCurrent	845443	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	0	usd
CY2023Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	89989	usd
CY2024Q2	upxi	Assets Available For Sale Vitamedica Current AssetsAvailableForSaleVitamedicaCurrent	0	usd
CY2023Q2	upxi	Assets Available For Sale Vitamedica Current AssetsAvailableForSaleVitamedicaCurrent	2599934	usd
CY2024Q2	upxi	Assets Available For Sale E Core Current AssetsAvailableForSaleECoreCurrent	0	usd
CY2023Q2	upxi	Assets Available For Sale E Core Current AssetsAvailableForSaleECoreCurrent	10332105	usd
CY2024Q2	upxi	Discontinued Assets Available For Sale Interactive Offers Non Current DiscontinuedAssetsAvailableForSaleInteractiveOffersNonCurrent	0	usd
CY2023Q2	upxi	Discontinued Assets Available For Sale Interactive Offers Non Current DiscontinuedAssetsAvailableForSaleInteractiveOffersNonCurrent	936054	usd
CY2024Q2	upxi	Discontinued Assets Available For Sale Vitamedica Non Current DiscontinuedAssetsAvailableForSaleVitamedicaNonCurrent	0	usd
CY2023Q2	upxi	Discontinued Assets Available For Sale Vitamedica Non Current DiscontinuedAssetsAvailableForSaleVitamedicaNonCurrent	2051214	usd
CY2024Q2	upxi	Discontinued Assets Available For Sale E Core Non Current DiscontinuedAssetsAvailableForSaleECoreNonCurrent	0	usd
CY2023Q2	upxi	Discontinued Assets Available For Sale E Core Non Current DiscontinuedAssetsAvailableForSaleECoreNonCurrent	12067333	usd
CY2024Q2	upxi	Acquisition Note Payable Current AcquisitionNotePayableCurrent	0	usd
CY2023Q2	upxi	Acquisition Note Payable Current AcquisitionNotePayableCurrent	5656620	usd
CY2024Q2	upxi	Discontinued Liabilities Interactive Offers Current DiscontinuedLiabilitiesInteractiveOffersCurrent	0	usd
CY2023Q2	upxi	Discontinued Liabilities Interactive Offers Current DiscontinuedLiabilitiesInteractiveOffersCurrent	792408	usd
CY2024Q2	upxi	Liabilities Of Discontinued Vita Medica Current LiabilitiesOfDiscontinuedVitaMedicaCurrent	0	usd
CY2023Q2	upxi	Liabilities Of Discontinued Vita Medica Current LiabilitiesOfDiscontinuedVitaMedicaCurrent	617174	usd
CY2024Q2	upxi	Discontinued Liabilities E Core Current DiscontinuedLiabilitiesECoreCurrent	0	usd
CY2023Q2	upxi	Discontinued Liabilities E Core Current DiscontinuedLiabilitiesECoreCurrent	3401983	usd
CY2024Q2	upxi	Acquisition Notes Payable Non Current AcquisitionNotesPayableNonCurrent	0	usd
CY2023Q2	upxi	Acquisition Notes Payable Non Current AcquisitionNotesPayableNonCurrent	7605085	usd
CY2024Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	usd
CY2023Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	4898548	usd
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	25000	shares
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	5000000	shares
CY2024Q2	us-gaap	Common Stocks Including Additional Paid In Capital CommonStocksIncludingAdditionalPaidInCapital	1045	usd
CY2023Q2	us-gaap	Common Stocks Including Additional Paid In Capital CommonStocksIncludingAdditionalPaidInCapital	1011	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	6515901	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	28341770	usd
CY2023Q2	us-gaap	Minority Interest MinorityInterest	-505147	usd
CY2024	us-gaap	Revenues Revenues	26000652	usd
CY2023	us-gaap	Revenues Revenues	36441695	usd
CY2024	us-gaap	Cost Of Revenue CostOfRevenue	13176073	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	15421715	usd
CY2024	us-gaap	Gross Profit GrossProfit	12824579	usd
CY2023	us-gaap	Gross Profit GrossProfit	21019980	usd
CY2024	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	5989727	usd
CY2023	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	6067392	usd
CY2024	us-gaap	Production And Distribution Costs ProductionAndDistributionCosts	8611702	usd
CY2023	us-gaap	Production And Distribution Costs ProductionAndDistributionCosts	9465149	usd
CY2024	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6771937	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6875575	usd
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	1169843	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	3664538	usd
CY2024	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2410431	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2568502	usd
CY2024	us-gaap	Depreciation Depreciation	1268355	usd
CY2023	us-gaap	Depreciation Depreciation	913246	usd
CY2024	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	336434	usd
CY2023	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	usd
CY2024	upxi	Gain Loss On The Sale Abandonment Of Assets In Relocation GainLossOnTheSaleAbandonmentOfAssetsInRelocation	569195	usd
CY2023	upxi	Gain Loss On The Sale Abandonment Of Assets In Relocation GainLossOnTheSaleAbandonmentOfAssetsInRelocation	0	usd
CY2024	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	7869425	usd
CY2023	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	3746301	usd
CY2024	upxi	Lease Impairment Of Business LeaseImpairmentOfBusiness	289969	usd
CY2023	upxi	Lease Impairment Of Business LeaseImpairmentOfBusiness	0	usd
CY2024	us-gaap	Operating Expenses OperatingExpenses	35287018	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	33300703	usd
CY2024	us-gaap	Operating Income Loss OperatingIncomeLoss	-22462439	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-12280723	usd
CY2024	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1770	usd
CY2024	upxi	Other Incom Expenses Net OtherIncomExpensesNet	-16443	usd
CY2023	upxi	Other Incom Expenses Net OtherIncomExpensesNet	38344	usd
CY2024	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-3124723	usd
CY2023	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-4716274	usd
CY2024	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3141166	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4676160	usd
CY2024	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-25603605	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-16956883	usd
CY2024	upxi	Income Tax Expense Benefit Gross IncomeTaxExpenseBenefitGross	332101	usd
CY2023	upxi	Income Tax Expense Benefit Gross IncomeTaxExpenseBenefitGross	3049293	usd
CY2024	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	332101	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3049293	usd
CY2024	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-25271504	usd
CY2023	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-13907590	usd
CY2024	upxi	Gain On Sale Of Infusionz And Select Assets GainOnSaleOfInfusionzAndSelectAssets	0	usd
CY2023	upxi	Gain On Sale Of Infusionz And Select Assets GainOnSaleOfInfusionzAndSelectAssets	-2212542	usd
CY2024	upxi	Gain Loss From The Sale Of Interactive Offers GainLossFromTheSaleOfInteractiveOffers	237670	usd
CY2023	upxi	Gain Loss From The Sale Of Interactive Offers GainLossFromTheSaleOfInteractiveOffers	0	usd
CY2024	upxi	Gain Loss From The Sale Of Vita Medica GainLossFromTheSaleOfVitaMedica	1948538	usd
CY2023	upxi	Gain Loss From The Sale Of Vita Medica GainLossFromTheSaleOfVitaMedica	0	usd
CY2024	upxi	Gain Loss From The Sale Of E Core GainLossFromTheSaleOfECore	-1737326	usd
CY2023	upxi	Gain Loss From The Sale Of E Core GainLossFromTheSaleOfECore	0	usd
CY2024	upxi	Gain Loss From The Sale Of Businesses GainLossFromTheSaleOfBusinesses	448882	usd
CY2023	upxi	Gain Loss From The Sale Of Businesses GainLossFromTheSaleOfBusinesses	-2212542	usd
CY2024	upxi	Income Loss On Discontinued Operations Infuisionz IncomeLossOnDiscontinuedOperationsInfuisionz	71976	usd
CY2023	upxi	Income Loss On Discontinued Operations Infuisionz IncomeLossOnDiscontinuedOperationsInfuisionz	-338418	usd
CY2024	upxi	Income Loss On Discontinued Operations Interactive Offers IncomeLossOnDiscontinuedOperationsInteractiveOffers	-187003	usd
CY2023	upxi	Income Loss On Discontinued Operations Interactive Offers IncomeLossOnDiscontinuedOperationsInteractiveOffers	-1729636	usd
CY2024	upxi	Income Loss On Discontinued Operations Vitamedica IncomeLossOnDiscontinuedOperationsVitamedica	213636	usd
CY2023	upxi	Income Loss On Discontinued Operations Vitamedica IncomeLossOnDiscontinuedOperationsVitamedica	-382449	usd
CY2024	upxi	Income Loss On Discontinued Operations Ecore IncomeLossOnDiscontinuedOperationsEcore	1065575	usd
CY2023	upxi	Income Loss On Discontinued Operations Ecore IncomeLossOnDiscontinuedOperationsEcore	1080379	usd
CY2024	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	1164184	usd
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-1370124	usd
CY2024	us-gaap	Income Loss Attributable To Noncontrolling Interest IncomeLossAttributableToNoncontrollingInterest	0	usd
CY2023	us-gaap	Income Loss Attributable To Noncontrolling Interest IncomeLossAttributableToNoncontrollingInterest	-559967	usd
CY2024	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-23658438	usd
CY2023	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-16930289	usd
CY2024	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-24.60
CY2023	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-15.56
CY2024	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	1.13
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-1.53
CY2024	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-23.03
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-18.94
CY2024	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-24.60
CY2023	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-15.56
CY2024	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	1.13
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-1.53
CY2024	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-23.03
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-18.94
CY2024	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1027232	shares
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	893943	shares
CY2024	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1027232	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	893943	shares
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	28786744	usd
CY2023	upxi	Amortization Of Common Stock Issuance For Services AmortizationOfCommonStockIssuanceForServices	140700	usd
CY2023	upxi	Stock Based Compensation Amortization Of Stock Options StockBasedCompensationAmortizationOfStockOptions	3664538	usd
CY2023	upxi	Issuance Of Common Stock For Acquisition Of E Core Amount IssuanceOfCommonStockForAcquisitionOfECoreAmount	6000000	usd
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	607004	usd
CY2023	upxi	Common Stock Issued For Cash Net Amount CommonStockIssuedForCashNetAmount	6127893	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-17490256	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	27836623	usd
CY2024	upxi	Stock Based Compensation Restricted Stock Grant Amount StockBasedCompensationRestrictedStockGrantAmount	212748	usd
CY2024	upxi	Stock Based Compensation Amortization Of Stock Options StockBasedCompensationAmortizationOfStockOptions	957095	usd
CY2024	upxi	Issuance Of Stock And Equity For Purchase Of Cygnet Amount IssuanceOfStockAndEquityForPurchaseOfCygnetAmount	667873	usd
CY2024	upxi	Issuance Of Stock For Conversion Of Debt Amount IssuanceOfStockForConversionOfDebtAmount	500000	usd
CY2024	us-gaap	Net Income Loss NetIncomeLoss	-23658438	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6515901	usd
CY2024	us-gaap	Profit Loss ProfitLoss	-23658438	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-16930289	usd
CY2024	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3678786	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3481748	usd
CY2024	upxi	Non Cash Loss On The Sale Of Infusionz And Select Assets Net NonCashLossOnTheSaleOfInfusionzAndSelectAssetsNet	0	usd
CY2023	upxi	Non Cash Loss On The Sale Of Infusionz And Select Assets Net NonCashLossOnTheSaleOfInfusionzAndSelectAssetsNet	-2212542	usd
CY2024	upxi	Gain On The Sale Of Vitamedica And Income From Discontinued Operations GainOnTheSaleOfVitamedicaAndIncomeFromDiscontinuedOperations	1948538	usd
CY2023	upxi	Gain On The Sale Of Vitamedica And Income From Discontinued Operations GainOnTheSaleOfVitamedicaAndIncomeFromDiscontinuedOperations	0	usd
CY2024	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	-1737326	usd
CY2023	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	0	usd
CY2024	upxi	Amortization Of Loan Costs AmortizationOfLoanCosts	115787	usd
CY2023	upxi	Amortization Of Loan Costs AmortizationOfLoanCosts	62408	usd
CY2024	upxi	Amortization Of Consideration Discount AmortizationOfConsiderationDiscount	1112676	usd
CY2023	upxi	Amortization Of Consideration Discount AmortizationOfConsiderationDiscount	969098	usd
CY2024	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	7869425	usd
CY2023	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	3746301	usd
CY2024	us-gaap	Inventory Write Down InventoryWriteDown	1812319	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	118990	usd
CY2024	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	336434	usd
CY2023	us-gaap	Tangible Asset Impairment Charges TangibleAssetImpairmentCharges	0	usd
CY2024	upxi	Increasedecreaseinloss On Sale Of Assets Related To Relocation Of Facility IncreasedecreaseinlossOnSaleOfAssetsRelatedToRelocationOfFacility	-569195	usd
CY2024	upxi	Gain Loss On Sale Of Interactive Offers GainLossOnSaleOfInteractiveOffers	237670	usd
CY2023	upxi	Gain Loss On Sale Of Interactive Offers GainLossOnSaleOfInteractiveOffers	0	usd
CY2024	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	344802	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	3139227	usd
CY2024	upxi	Minority Interest From Distributions To Noncontrolling Interest Holders MinorityInterestFromDistributionsToNoncontrollingInterestHolders	0	usd
CY2023	upxi	Minority Interest From Distributions To Noncontrolling Interest Holders MinorityInterestFromDistributionsToNoncontrollingInterestHolders	-559967	usd
CY2024	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	0	usd
CY2023	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	1770	usd
CY2024	us-gaap	Share Based Compensation ShareBasedCompensation	1169843	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	3664538	usd
CY2024	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-675709	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	364665	usd
CY2024	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-2651252	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1366269	usd
CY2024	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-106610	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-287797	usd
CY2024	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	302050	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	4238	usd
CY2024	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-944020	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	389458	usd
CY2024	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	101305	usd
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4894751	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-7421529	usd
CY2024	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	4793374	usd
CY2023	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	7624206	usd
CY2024	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-101377	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	202677	usd
CY2024	upxi	Payment To Acquire Lucky Tail PaymentToAcquireLuckyTail	0	usd
CY2023	upxi	Payment To Acquire Lucky Tail PaymentToAcquireLuckyTail	3528239	usd
CY2024	us-gaap	Proceeds From Sale Of Longterm Investments ProceedsFromSaleOfLongtermInvestments	2100000	usd
CY2023	us-gaap	Proceeds From Sale Of Longterm Investments ProceedsFromSaleOfLongtermInvestments	0	usd
CY2024	upxi	Proceeds From The Sale Of Interactive Offers Net Of Liabilities Paid ProceedsFromTheSaleOfInteractiveOffersNetOfLiabilitiesPaid	203025	usd
CY2023	upxi	Proceeds From The Sale Of Interactive Offers Net Of Liabilities Paid ProceedsFromTheSaleOfInteractiveOffersNetOfLiabilitiesPaid	0	usd
CY2024	us-gaap	Payments To Acquire Business Three Net Of Cash Acquired PaymentsToAcquireBusinessThreeNetOfCashAcquired	539348	usd
CY2023	us-gaap	Payments To Acquire Business Three Net Of Cash Acquired PaymentsToAcquireBusinessThreeNetOfCashAcquired	1050000	usd
CY2024	upxi	Proceeds From The Sale Of Infusionz And Selected Assets ProceedsFromTheSaleOfInfusionzAndSelectedAssets	0	usd
CY2023	upxi	Proceeds From The Sale Of Infusionz And Selected Assets ProceedsFromTheSaleOfInfusionzAndSelectedAssets	5492532	usd
CY2024	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	932565	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	937564	usd
CY2024	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	831112	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-23271	usd
CY2024	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-4206823	usd
CY2023	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-2551587	usd
CY2024	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3375711	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2574858	usd
CY2024	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0	usd
CY2023	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	6305406	usd
CY2024	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	0	usd
CY2023	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	6127893	usd
CY2024	upxi	Payments To Acquire Notes Receivables PaymentsToAcquireNotesReceivables	246761	usd
CY2023	upxi	Payments To Acquire Notes Receivables PaymentsToAcquireNotesReceivables	751152	usd
CY2024	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	100000	usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	0	usd
CY2024	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	2650000	usd
CY2024	upxi	Proceeds On Note Payable On Building ProceedsOnNotePayableOnBuilding	0	usd
CY2023	upxi	Proceeds On Note Payable On Building ProceedsOnNotePayableOnBuilding	3000000	usd
CY2024	upxi	Repayment On Note Payable On Building RepaymentOnNotePayableOnBuilding	207028	usd
CY2023	upxi	Repayment On Note Payable On Building RepaymentOnNotePayableOnBuilding	158434	usd
CY2024	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	usd
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1470000	usd
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-353789	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	6032901	usd
CY2024	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	0	usd
CY2023	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	-6318234	usd
CY2024	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-353789	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-285333	usd
CY2024	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4417428	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1411899	usd
CY2024	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	586551	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations	-1245615	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4492292	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7149806	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	661415	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4492292	usd
CY2024	us-gaap	Interest Paid Net InterestPaidNet	839000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	2278292	usd
CY2024	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	usd
CY2024	upxi	Proceedsfromnon Cash Proceeds In The Sale Of Vitamedica ProceedsfromnonCashProceedsInTheSaleOfVitamedica	1900000	usd
CY2023	upxi	Proceedsfromnon Cash Proceeds In The Sale Of Vitamedica ProceedsfromnonCashProceedsInTheSaleOfVitamedica	0	usd
CY2024	upxi	Common Stock Issued For Acquisition Of Cygnet CommonStockIssuedForAcquisitionOfCygnet	162727	usd
CY2023	upxi	Common Stock Issued For Acquisition Of Cygnet CommonStockIssuedForAcquisitionOfCygnet	0	usd
CY2024	upxi	Debt Issued For Acquisition Of Cygnet DebtIssuedForAcquisitionOfCygnet	300000	usd
CY2023	upxi	Debt Issued For Acquisition Of Cygnet DebtIssuedForAcquisitionOfCygnet	0	usd
CY2024	upxi	Net Bloomios Non Cash Payment Of Receivables NetBloomiosNonCashPaymentOfReceivables	845443	usd
CY2023	upxi	Net Bloomios Non Cash Payment Of Receivables NetBloomiosNonCashPaymentOfReceivables	0	usd
CY2024	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	0	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	140700	usd
CY2024	upxi	Issuance Of Stock For Interest Expense IssuanceOfStockForInterestExpense	0	usd
CY2023	upxi	Issuance Of Stock For Interest Expense IssuanceOfStockForInterestExpense	607004	usd
CY2024	upxi	Common Stock Issued For The Repayment Of Convertible Note Payable CommonStockIssuedForTheRepaymentOfConvertibleNotePayable	500000	usd
CY2023	upxi	Common Stock Issued For The Repayment Of Convertible Note Payable CommonStockIssuedForTheRepaymentOfConvertibleNotePayable	0	usd
CY2024	upxi	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed	0	usd
CY2023	upxi	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed	-7712168	usd
CY2024	upxi	Issuance Of Stock For Acquisition Of E Core IssuanceOfStockForAcquisitionOfECore	0	usd
CY2023	upxi	Issuance Of Stock For Acquisition Of E Core IssuanceOfStockForAcquisitionOfECore	6000000	usd
CY2024	upxi	Payment To Acquire Available For Sale Securities PaymentToAcquireAvailableForSaleSecurities	0	usd
CY2023	upxi	Payment To Acquire Available For Sale Securities PaymentToAcquireAvailableForSaleSecurities	1026043	usd
CY2024Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	606885	usd
CY2023Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	1125394	usd
CY2022Q2	us-gaap	Accounts Receivable Net AccountsReceivableNet	760729	usd
CY2024Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	61750	usd
CY2023Q2	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0	usd
CY2024	upxi	Bad Debt Expense BadDebtExpense	24500	shares
CY2023	upxi	Bad Debt Expense BadDebtExpense	4750	shares
CY2024Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	465535	usd
CY2024Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	966021	usd
CY2023Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	4804299	usd
CY2024Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	605470	usd
CY2023Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	154400	usd
CY2024	upxi	Lease Term1 LeaseTerm1	P5Y
CY2024	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	3594745	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	2889158	usd
CY2024Q2	us-gaap	Deferred Revenue DeferredRevenue	235255	usd
CY2023Q2	us-gaap	Deferred Revenue DeferredRevenue	0	usd
CY2024Q2	us-gaap	Deferred Revenue DeferredRevenue	235255	usd
CY2023Q2	us-gaap	Deferred Revenue DeferredRevenue	0	usd
CY2022Q2	us-gaap	Deferred Revenue DeferredRevenue	0	usd
CY2024	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	336434	usd
CY2024	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets	569195	usd
CY2024	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	4274680	usd
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	857143	usd
CY2023Q2	upxi	Intangible Assets Available For Sale IntangibleAssetsAvailableForSale	716944	usd
CY2024	us-gaap	Advertising Expense AdvertisingExpense	3353361	usd
CY2023	us-gaap	Advertising Expense AdvertisingExpense	4271469	usd
CY2024Q2	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	6100000	usd
CY2024Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	19860	usd
CY2024Q2	upxi	Additional Issuance Shares AdditionalIssuanceShares	38	shares
CY2024Q2	upxi	Additional Issuance Shares Of Common Stock AdditionalIssuanceSharesOfCommonStock	202183	shares
CY2024	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	295133	shares
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	324750	shares
CY2024	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	15253383	usd
CY2023	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	28485470	usd
CY2024Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	465535	usd
CY2023Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	0	usd
CY2024Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	966021	usd
CY2023Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	4804299	usd
CY2024Q2	us-gaap	Inventory Noncurrent InventoryNoncurrent	1431556	usd
CY2023Q2	us-gaap	Inventory Noncurrent InventoryNoncurrent	4804299	usd
CY2024	us-gaap	Inventory Write Down InventoryWriteDown	1812319	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	118990	usd
CY2024Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	605470	usd
CY2023Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	154400	usd
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7600360	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9136030	usd
CY2024Q2	us-gaap	Property Plant And Equipment Other Accumulated Depreciation PropertyPlantAndEquipmentOtherAccumulatedDepreciation	1268288	usd
CY2023Q2	us-gaap	Property Plant And Equipment Other Accumulated Depreciation PropertyPlantAndEquipmentOtherAccumulatedDepreciation	1693407	usd
CY2024Q2	us-gaap	Land Available For Sale LandAvailableForSale	4005516	usd
CY2023Q2	us-gaap	Land Available For Sale LandAvailableForSale	4611248	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2356556	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2831375	usd
CY2024	us-gaap	Depreciation Expense On Reclassified Assets DepreciationExpenseOnReclassifiedAssets	1268355	usd
CY2023	us-gaap	Depreciation Expense On Reclassified Assets DepreciationExpenseOnReclassifiedAssets	913246	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	10018484	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	9778613	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	239871	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	10018484	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	4237814	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	6924982	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	76758	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	76758	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	76758	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	9596	usd
CY2024Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	239871	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	502188	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	1112280	usd
CY2024	upxi	Description Of Lease Term DescriptionOfLeaseTerm	Our lease terms may include one or more options to extend the lease terms, for periods from one year to 20 years
CY2024Q2	upxi	Operating Leases Minimum Payments OperatingLeasesMinimumPayments	95548	usd
CY2023Q2	upxi	Operating Leases Minimum Payments OperatingLeasesMinimumPayments	111796	usd
CY2024	upxi	Lease Expense Additional LeaseExpenseAdditional	106100	usd
CY2023	upxi	Lease Expense Additional LeaseExpenseAdditional	134700	usd
CY2024	us-gaap	Operating Lease Expense OperatingLeaseExpense	7640	usd
CY2023	us-gaap	Operating Lease Expense OperatingLeaseExpense	6744	usd
CY2024Q2	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	1031714	usd
CY2024Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	762364	usd
CY2024Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	504795	usd
CY2024Q2	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	486733	usd
CY2024Q2	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	221715	usd
CY2024Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	3007321	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	243001	usd
CY2024Q2	upxi	Accrued Adverse Lease Obligation AccruedAdverseLeaseObligation	2764320	usd
CY2024Q2	upxi	Less Current Portion LessCurrentPortion	-1031714	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	1732606	usd
CY2024	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P47M
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.050	pure
CY2023	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2	P29M
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.050	pure
CY2024	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	669260	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	228147	usd
CY2024	us-gaap	Interest Expense Other InterestExpenseOther	99633	usd
CY2023	us-gaap	Interest Expense Other InterestExpenseOther	28043	usd
CY2024	us-gaap	Operating Lease Cost OperatingLeaseCost	16181	usd
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	16804	usd
CY2024	us-gaap	Short Term Lease Cost ShortTermLeaseCost	670173	usd
CY2023	us-gaap	Short Term Lease Cost ShortTermLeaseCost	772929	usd
CY2024	us-gaap	Variable Lease Cost VariableLeaseCost	169309	usd
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	29113	usd
CY2024	us-gaap	Lease Cost LeaseCost	1624556	usd
CY2023	us-gaap	Lease Cost LeaseCost	1075036	usd
CY2024Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	312500	usd
CY2023Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	666495	usd
CY2024Q2	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	28539	usd
CY2023Q2	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	37429	usd
CY2024Q2	us-gaap	Accrued Liabilities For Commissions Expense And Taxes AccruedLiabilitiesForCommissionsExpenseAndTaxes	0	usd
CY2023Q2	us-gaap	Accrued Liabilities For Commissions Expense And Taxes AccruedLiabilitiesForCommissionsExpenseAndTaxes	1360000	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	395368	usd
CY2023Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	375870	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	736407	usd
CY2023Q2	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	2439794	usd
CY2024Q2	us-gaap	Acquisition Costs Cumulative AcquisitionCostsCumulative	413152	usd
CY2023Q2	us-gaap	Acquisition Costs Cumulative AcquisitionCostsCumulative	152500	usd
CY2024	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	100000	usd
CY2022Q2	us-gaap	Debt Instrument Increase Decrease For Period Net DebtInstrumentIncreaseDecreaseForPeriodNet	1500000	usd
CY2022Q2	us-gaap	Short Term Debt Interest Rate Increase ShortTermDebtInterestRateIncrease	0.085	pure
CY2022Q2	upxi	Additional Percentage Rate AdditionalPercentageRate	0.035	pure
CY2023	upxi	Common Stock For Prepayment Of Interest On Note Payable Shares CommonStockForPrepaymentOfInterestOnNotePayableShares	6700	shares
CY2023	upxi	Common Stock For Prepayment Of Interest On Note Payable Value CommonStockForPrepaymentOfInterestOnNotePayableValue	607020	usd
CY2024Q1	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	25081	shares
CY2024Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	500000	usd
CY2024Q1	upxi	Common Stock Per Share Price CommonStockPerSharePrice	19.94
CY2024Q1	us-gaap	Stock Issued During Period Shares Employee Benefit Plan StockIssuedDuringPeriodSharesEmployeeBenefitPlan	5000	shares
CY2024Q1	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	85000	usd
CY2024Q1	upxi	Common Stocks Par Or Stated Value Per Share CommonStocksParOrStatedValuePerShare	17
CY2024Q4	upxi	Reverse Stock Split Rate ReverseStockSplitRate	20 to 1
CY2024Q4	upxi	Total Issued And Outstanding Common Stock Shares Post Reverse Split TotalIssuedAndOutstandingCommonStockSharesPostReverseSplit	1040886	shares
CY2024	upxi	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Term ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm	P5Y
CY2023	upxi	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Term ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm	P6Y6M
CY2024	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	12700	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	349260	usd
CY2024	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	-344801	usd
CY2023	us-gaap	Deferred Other Tax Expense Benefit DeferredOtherTaxExpenseBenefit	-3601298	usd
CY2024	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-332101	usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-3049293	usd
CY2024	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.2100	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Deductions Medicare Prescription Drug Benefit EffectiveIncomeTaxRateReconciliationDeductionsMedicarePrescriptionDrugBenefit	0.0027	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Deductions Medicare Prescription Drug Benefit EffectiveIncomeTaxRateReconciliationDeductionsMedicarePrescriptionDrugBenefit	0.0504	pure
CY2024	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.0005	pure
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.0024	pure
CY2024	upxi	Tax Return To Provision TaxReturnToProvision	0.0000	pure
CY2023	upxi	Tax Return To Provision TaxReturnToProvision	-0.0267	pure
CY2023	srt	Mortgage Loans On Real Estate Interest Rate MortgageLoansOnRealEstateInterestRate	0.0181	pure
CY2024	upxi	Other Net OtherNet	0.0553	pure
CY2023	upxi	Other Net OtherNet	0.0090	pure
CY2024	us-gaap	Public Utilities Allowance For Funds Used During Construction Rate PublicUtilitiesAllowanceForFundsUsedDuringConstructionRate	0.2543	pure
CY2023	us-gaap	Public Utilities Allowance For Funds Used During Construction Rate PublicUtilitiesAllowanceForFundsUsedDuringConstructionRate	0	pure
CY2024	upxi	Provision For Income Taxes ProvisionForIncomeTaxes	0.0138	pure
CY2023	upxi	Provision For Income Taxes ProvisionForIncomeTaxes	0.2583	pure
CY2024	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	4405547	usd
CY2023	us-gaap	Other Nonoperating Gains Losses OtherNonoperatingGainsLosses	752863	usd
CY2024	upxi	Right Of Use Assets RightOfUseAssets	98987	usd
CY2023	upxi	Right Of Use Assets RightOfUseAssets	0	usd
CY2024	upxi	Inventory Write Off InventoryWriteOff	981758	usd
CY2023	upxi	Inventory Write Off InventoryWriteOff	0	usd
CY2024	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	3159477	usd
CY2023	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	1015997	usd
CY2024	upxi	Amortization Of Intangibles Assets AmortizationOfIntangiblesAssets	1034959	usd
CY2023	upxi	Amortization Of Intangibles Assets AmortizationOfIntangiblesAssets	1741870	usd
CY2024	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	2323784	usd
CY2023	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	1999688	usd
CY2024	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	16797	usd
CY2023	us-gaap	Allowance For Doubtful Accounts Receivable Recoveries AllowanceForDoubtfulAccountsReceivableRecoveries	56112	usd
CY2024	upxi	Accrued Compensations AccruedCompensations	27540	usd
CY2023	upxi	Accrued Compensations AccruedCompensations	19323	usd
CY2024	us-gaap	Recognition Of Deferred Revenue RecognitionOfDeferredRevenue	0	usd
CY2023	us-gaap	Recognition Of Deferred Revenue RecognitionOfDeferredRevenue	18196	usd
CY2023	us-gaap	Other Income OtherIncome	7	usd
CY2024	us-gaap	Other Income OtherIncome	7	usd
CY2024	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	-6100000	usd
CY2023	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	0	usd
CY2024	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	5948858	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	5604056	usd
CY2024Q2	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	44916500	usd
CY2023Q2	us-gaap	Deferred Tax Assets Charitable Contribution Carryforwards DeferredTaxAssetsCharitableContributionCarryforwards	21258000	usd
CY2022Q2	upxi	Valuation Reserves For Inventory ValuationReservesForInventory	2506514	usd
CY2024Q2	upxi	Valuation Reserves For Inventory ValuationReservesForInventory	6100000	usd
CY2022Q2	us-gaap	Short Term Debt Interest Rate Increase ShortTermDebtInterestRateIncrease	0.085	pure

Files In Submission

Name	View Source	Status
0001477932-24-008123-index-headers.html	Edgar Link	pending
0001477932-24-008123-index.html	Edgar Link	pending
0001477932-24-008123.txt	Edgar Link	pending
0001477932-24-008123-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
upxi-20240630.xsd	Edgar Link	pending
upxi_10k.htm	Edgar Link	pending
upxi_10kimg10.jpg	Edgar Link	pending
upxi_10kimg11.jpg	Edgar Link	pending
upxi_10kimg12.jpg	Edgar Link	pending
upxi_10kimg13.jpg	Edgar Link	pending
upxi_10kimg14.jpg	Edgar Link	pending
upxi_10kimg15.jpg	Edgar Link	pending
upxi_10kimg8.jpg	Edgar Link	pending
upxi_10kimg9.jpg	Edgar Link	pending
upxi_ex311.htm	Edgar Link	pending
upxi_ex312.htm	Edgar Link	pending
upxi_ex321.htm	Edgar Link	pending
upxi_ex322.htm	Edgar Link	pending
upxi-20240630_cal.xml	Edgar Link	unprocessable
upxi-20240630_def.xml	Edgar Link	unprocessable
upxi-20240630_lab.xml	Edgar Link	unprocessable
upxi-20240630_pre.xml	Edgar Link	unprocessable
upxi_10k_htm.xml	Edgar Link	completed
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$UPXI
UPEXI, INC. Stock $upxi

2024 Q4 Form 10-K Financial Statement

#000147793224008123 Filed on December 16, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$UPXI UPEXI, INC. Stock $upxi

2024 Q4 Form 10-K Financial Statement

#000147793224008123 Filed on December 16, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$UPXI
UPEXI, INC. Stock $upxi